Review of LDL-C lowering with focus on new and emerging agents

Abstract

Elevated LDL-C levels are the primary treatable cause of ASCVD. Decades of CVOTs involving multiple therapies for lowering LDL-C demonstrate remarkably consistent reductions in ASCVD events, proportional to LDL-C reductions. Statins remain the foundation for LDL-C-lowering treatment; however, their efficacy at doses tolerated by the patient is not always sufficient to achieve goal levels. Existing statin adjuncts can efficiently and safely provide further LDL-Clowering. Further, with the likely advent of additional LDL-lowering agents in the near future, even better LDL-C control should become easier and more universally achievable.